FDA Clears Serina's Advanced Parkinson's Disease Drug for Clinical Trial
Serina Therapeutics receives FDA IND clearance for SER-252, advancing toward Phase 1b clinical study for advanced Parkinson's disease treatment using POZ platform technology.
Serina Therapeutics receives FDA IND clearance for SER-252, advancing toward Phase 1b clinical study for advanced Parkinson's disease treatment using POZ platform technology.
Serina Therapeutics’ SER-252 for advanced Parkinson's gains FDA support for a registrational study via the 505(b)(2) NDA pathway. The POZ Platform enables continuous dopaminergic stimulation, aiming to improve motor fluctuations.